The licensing agreement paves the way for the further development of Oncomab’s
technology to create a Cripto-1 mAB as an immunotherapy treatment for cancers.
Bioceros is one of Europe’s premier providers of services related to the pre-clinical
development of mAB’s and generation of GMP-ready protein producing cell lines (CHO and
PER.C6®). The Company currently provides services to multiple customers from the biotech
and food industries.

Bioceros uses its validated technology platform and pre-clinical development expertise to
design and develop effective proprietary therapeutic mAB’s.

There is a massive global market for mAB treatments. According to leading pharmaceutical
industry research group, GBI Pharmaceutical Research, the global mAB market is worth
$46.8 billion in sales, this year.

Cripto-1 is a protein found in high levels on the surface of a number of different types of
malignant tumour cells. It facilitates growth of the tumor cells, and contributes to their
spreading throughout the body. The antibody works by binding to the Cripto-1 molecule
interfering with local development of the tumor, and preventing distant seeding of tumor
cells.

The antibody may be administered in combination with cytotoxic drugs (chemotherapy
drugs) to create an even more lethal potent additive effect on tumour cell destruction.
The Licensing Agreement with Bioceros is by way of a 70 (Prima):30 (Bioceros) project split,
and the work will be undertaken by Bioceros.

Prima’s agreement, through Oncomab, for the out-licensing and development of Cripto-1
expands the company’s clinical development programs in the area of immunotherapy
cancer treatments.

Prima managing director Martin Rogers said: “We are delighted to have engaged such a
high quality partner, as Bioceros, to license the development of Cripto-1. They are industry
experts in their field, and we look forward to seeing the benefits of their work with Cripto-1,
as we continue to grow our business in the area of cancer immunotherapy treatments.”

Bram Bout, Bioceros’ CEO commented: “This deal fits well in our strategy to use our
technology platform to (co) develop early stage monoclonal antibody products. We are
excited about working on the Cripto-1 antibodies together with Prima. Bioceros is
experienced in pre-clinical development of mAB’s, and Prima has extensive complementary
expertise in clinical development of biotech products, which together allows us to leverage
the Cripto-1 mAB’s significantly”.